Related references
Note: Only part of the references are listed.Salvage Therapy with 177Lu-Octreotate in Patients with Bronchial and Gastroenteropancreatic Neuroendocrine Tumors
Martijn van Essen et al.
JOURNAL OF NUCLEAR MEDICINE (2010)
[90Yttrium-DOTA]-TOC Response Is Associated With Survival Benefit in Iodine-Refractory Thyroid Cancer Long-term Results of a Phase 2 Clinical Trial
Fabienne Iten et al.
CANCER (2009)
New response evaluation criteria in solid tumours: Revised RECIST guideline (version 1.1)
E. A. Eisenhauer et al.
EUROPEAN JOURNAL OF CANCER (2009)
Long-term evaluation of renal toxicity after peptide receptor radionuclide therapy with 90Y-DOTATOC and 177Lu-DOTATATE:: the role of associated risk factors
Lisa Bodei et al.
EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING (2008)
Response to [90Yttrium-DOTA]-TOC treatment is associated with long-term survival benefit in metastasized medullary thyroid cancer:: A phase II clinical trial
Fabienne Iten et al.
CLINICAL CANCER RESEARCH (2007)
TNM staging of foregut (neuro)endocrine tumors:: a consensus proposal including a grading system
G. Rindi et al.
VIRCHOWS ARCHIV (2006)
50-year appraisal of gastrinoma: Recommendations for staging and treatment
EC Ellison et al.
JOURNAL OF THE AMERICAN COLLEGE OF SURGEONS (2006)
Gastrinoma (duodenal and pancreatic)
Robert T. Jensen et al.
NEUROENDOCRINOLOGY (2006)
Management of metastatic endocrine tumours
U Plöckinger et al.
BEST PRACTICE & RESEARCH CLINICAL GASTROENTEROLOGY (2005)
Chemotherapy
R Arnold et al.
BEST PRACTICE & RESEARCH CLINICAL GASTROENTEROLOGY (2005)
Radiolabeled somatostatin analog [177Lu-DOTA0,Tyr3] octreotate in patients with endocrine gastroenteropancreatic tumors
DJ Kwekkeboom et al.
JOURNAL OF CLINICAL ONCOLOGY (2005)
Treatment of patients with gastro-entero-pancreatic (GEP) tumours with the novel radiolabelled somatostatin analogue [177Lu-DOTA0,Tyr3]octreotate
DJ Kwekkeboom et al.
EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING (2003)
Phase I study of peptide receptor radionuclide therapy with [111In-DTPA0]octreotide:: The Rotterdam experience
R Valkema et al.
SEMINARS IN NUCLEAR MEDICINE (2002)
Indium-111-pentetreotide prolongs survival in gastroenteropancreatic malignancies
LB Anthony et al.
SEMINARS IN NUCLEAR MEDICINE (2002)
Somatostatin receptor-targeted radionuclide therapy of tumors: Preclinical and clinical findings
M de Jong et al.
SEMINARS IN NUCLEAR MEDICINE (2002)
Prospective study of the antitumor efficacy of long-term octreotide treatment in patients with progressive metastatic gastrinoma
H Shojamanesh et al.
CANCER (2002)
[177Lu-DOTA0,Tyr3]octreotate:: comparison with [111In-DTPA0]octreotide in patients
DJ Kwekkeboom et al.
EUROPEAN JOURNAL OF NUCLEAR MEDICINE (2001)
The clinical value of [90Y-DOTA]-D-Phe1-Tyr3-octreotide (90Y-DOTATOC) in the treatment of neuroendocrine tumours:: A clinical phase II study
C Waldherr et al.
ANNALS OF ONCOLOGY (2001)